VIENNA, Va.–(BUSINESS WIRE)–

CEL-SCI Corporation (NYSE MKT:CVM) today announced that it enrolled 20 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) during August 2014. This brings the total study enrollment to 252 patients.

“Given that summer months generally have a slower rate of enrollment for clinical trials, our goal was to maintain the enrollment level compared to the three months prior to the summer. In fact, we did better. We continue to add more centers and countries to the study. As we head into the fall, we believe the pace of patient enrollment will further increase,” stated CEL-SCI Chief Executive Officer Geert Kersten.

About Multikine Phase III Study

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.

About Multikine

Multikine* (Leukocyte Interleukin, Injection) is an investigational immunotherapeutic agent that is being tested in an open-label, randomized, controlled, global pivotal Phase III clinical trial as a potential first-line treatment for advanced primary head and neck cancer. If approved for use following completion of CEL-SCI’s clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body’s natural immune system in the fight against tumors. CEL-SCI is aiming to complete enrollment of subjects to the Phase III head and neck cancer study by the end of 2015. The trial is expected to expand into a total of approximately 100 clinical centers in about 20 countries.

In October 2013, CEL-SCI announced that it had signed a CRADA (Cooperative Research and Development Agreement) with the U.S. Naval Medical Center, San Diego, to develop Multikine as a potential treatment for HIV/HPV co-infected men and women with peri-anal warts. CEL-SCI also announced that it entered into two new co-development agreements with Ergomed to further clinically develop Multikine for cervical dysplasia/neoplasia in women who are co-infected with HIV and HPV and for peri-anal warts in men and women who are co-infected with HIV and HPV.

To read the entire article and join the discussion please visit the following link: http://www.renewablesbiz.com/article/14/08/all-eyes-boston-will-new-commercial-food-waste-ban-lead-boom-waste-energy

EVEN YEHUDA, Israel, August 7, 2014 /PRNewswire/ —

Bluesphere Corp. (BLSP) (the “Company” or “Bluesphere”), a clean energy company that develops, manages and owns waste-to-energy projects, announced today a newly published report authored by three U.S. government agencies outlines new federal initiatives to support exponential growth in the private biogas waste-to-energy sector. The Biogas Opportunities Roadmap, published August 1st by the U.S. Department of Agriculture, U.S. Environmental Protection Agency, and U.S. Department of Energy concluded that:

Developing a viable biogas industry in the U.S. can boost the economy and provide a reliable, distributed source of renewable energy while reducing greenhouse gas emissions
2,000 biogas sites operate in the U.S. today, and more than 11,000 additional biogas systems could be deployed to handle organic waste and produce energy and biogas system co-products
Realizing the full potential of the biogas industry will require support from federal agencies, greater investment, expanded markets for biogas and biogas products, and increased R&D
The benefits of biogas systems are clear. The task ahead is to reduce barriers and promote financial opportunities to move forward in developing a robust biogas industry
In the Biogas Opportunities Roadmap, the federal agencies identify programs that will promote biogas utilization and help the private sector voluntarily realize the full potential of biogas systems. These programs include:

Using existing agency programs to leverage over $10 million in research funding
Fostering investments in biogas systems including reviewing government procurement programs for products of biogas systems
Strengthening markets for biogas systems and system products including by modernizing existing Federal incentives
Improving communication and coordination by establishing a Biogas Opportunities Roadmap Working Group that will include participation from DOE and EPA, as well as the dairy and biogas industries
“The potential for biogas to increase renewable energy production, reduce landfill waste, benefit the environment, and spur economic growth in the U.S. is significant. We are very pleased to see the U.S. government publish a report that outlines these benefits and opportunities. Bluesphere is actively working in several U.S. states to develop biogas facilities. We have brought our global expertise in building and operating waste-to-energy facilities to the U.S. market and we’re finding very strong interest in the value proposition we have to offer. We are eager to expand our operations in the U.S. in conjunction with some major partners and to capitalize on biogas opportunities,” stated Bluesphere CEO Shlomi Palas.

Bluesphere has begun design and engineering work, and is scheduled to break ground in 2014 on a 5.2 MW waste-to-energy anaerobic digester in Charlotte, North Carolina. The Company is also developing in a 3.2 MW waste-to-energy project in Rhode Island and has a Memorandum of Understanding to develop a 5.2 MW waste-to-energy project in Massachusetts.

JERUSALEM, August 19, 2014 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Intellectual Property Department of Spain has granted the Company’s patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins.”

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD[TM]) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). Having completed separate Phase IIa clinical trials, the company anticipates the initiation of separate Phase IIb clinical trials, in patients with both type 1 and type 2 diabetes under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition the company is developing an oral GLP-1 analog capsule (ORMD-0901).

For more information, the content of which is not part of this press release, please visithttp://www.oramed.com

Pompano Beach, Fla., Aug. 15, 2014 (GLOBE NEWSWIRE) — DS Healthcare Group, Inc. (DSKX), a leading developer of personal care products, today announced financial results for the three and six months ended June 30, 2014.

.

Net revenues were $3,744,000, up 9% over Q2 2013

.

Gross margins increase to 52% from 48% in Q2 2013

.

Gross profits increase to $1,942,000 up 21% over Q2 2013

.

Net loss narrows 16% to $(633,000) from Q2 2013

Net revenues were $3,744,434 for the three months ended June 30, 2014, an increase of 9.1% over revenues of $3,431,154 for the three months ended June 30, 2013. Revenue growth in the second quarter was driven by double-digit, year-over-year sales growth at the Company’s Mexican subsidiary, as well increased sell-through in foreign markets. Domestic sales declined in the quarter due to $1 million in backorders that were pending completion and shipment prior to the end of the quarter.

Gross margin increased to 51.9% in the second quarter of 2014 from 46.7% in the same quarter of the prior year as a result of improved production efficiencies, improved pricing from suppliers, and cost cutting efforts including reduced payroll. Gross profits were up 21% to $1,941,536 in the second quarter of 2014, as compared to $1,601,086 in the second quarter of 2013. Selling and marketing costs increased by 34% to $1,194,238 in the second quarter of 2014 from $894,366 in the same period last year. General and administrative costs declined by 2% to $1,338,536 in the three months ended June 30, 2014, as compared to $1,369,558 in the same period of 2013. DS Healthcare’s net loss narrowed by 16% to $(633,339) or $(0.04) per basic and diluted share in the second quarter of 2014 from $(757,063) or $(0.06) per basic and diluted share in the same period of 2013.

For the six months ended June 30, 2014 net revenues were $6,429,397, a 13% decline from revenues of $7,392,846 for the six months ended June 30, 2013. Net revenue growth at the Company’s Mexican subsidiary, as well increased sell-through in foreign markets was offset by a decline in domestic sales due to backorders that were pending completion and shipment.

Gross margin increased to 53.3% in the first half of 2014 from 45.7% in the first half of the prior year, as a result of improved production efficiencies, improved cost from suppliers, and cost cutting efforts including payroll. Gross profits were up 1.4% to $3,423,981 in the first half of 2014, as compared to $3,375,769 in the first half of 2013. Selling and marketing costs increased by 31% to $2,164,260 in the six months ended June 30, 2014 from $1,651,364 in the same period last year. General and administrative costs decreased by 7% to $2,672,480 in the first two quarters of 2014, as compared to $2,878,234 in the same period of 2013. DS Healthcare’s net loss increased by 22% to $(1,479,120) or $(0.09) per basic and diluted share in the first half of 2014 from $(1,215,056) or $(0.10) per basic and diluted share in the same period of 2013.

On June 30, 2014 the Company had cash and cash equivalents of $773,055 and working capital of $3,264,514. Total stockholders’ equity on June 30, 2014 was $4,852,418.

VIENNA, Va.–(BUSINESS WIRE)–

CEL-SCI Corporation (NYSE MKT:CVM) today announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) has added Centre Hospitalier Universitaire de Québec (CHUQ)’s L’Hotel Dieu de Quebec to its growing number of clinical sites in North America. CHUQ is a network of three teaching hospitals affiliated with the medical school of Université Laval and several specialized institutions in Quebec City. CEL-SCI plans to activate additional clinical sites for accelerated patient enrollment in Canada.

The Principal Investigator for CEL-SCI’s Phase III trial at CHUQ is Dr. André Fortin, a radiation oncologist and visiting professor. He is responsible for the research protocols of radiation therapy for the oncology group at CHUQ. Dr. Fortin has extensive expertise in the treatment of cancers using radiation therapy for head and neck, pulmonary, and digestive cancers. He is very involved in clinical research within the department as evidenced by his numerous publications.

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only. CEL-SCI’s Multikine investigational immunotherapy is intended to create an anti-tumor immune response to reduce local/regional tumor recurrence and thereby increase the survival rate of these patients.

“We are adding many additional centers in Canada and the U.S. for the world’s largest Phase III trial in head and neck cancer. This will hopefully keep us on schedule to complete global enrollment with approximately 880 patients by the end of 2015,” stated CEL-SCI Chief Executive Officer Geert Kersten.

About Multikine Phase III Study

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.

Pompano Beach, Fla., Aug. 6, 2014 (GLOBE NEWSWIRE) — DS Healthcare Group, Inc. (DSKX), a leading developer of personal care products and specialty pharmaceuticals, announced today it has signed a distribution agreement with Drogaria Venancio, a leading Rio de Janerio-based pharmacy chain. Drogaria Venancio will sell DS Healthcare’s clinically proven personal care products including its Revita and Spectral hair re-growth and hair care products. DS Laboratories, its flagship line can already be found on retail shelves throughout Rio de Janeiro. Drogaria Venancio operates wholesale distribution centers and premium retail pharmacy locations. Founded in 1979, the pharmacy chain employs 1600 people.

This marks DS Healthcare’s third distribution agreement in Brazil and it’s second in Rio de Janeiro. DS Healthcare’s have already been selling through CSB Drogaria which has two retail pharmacy chains with 85 stores in Rio de Janeiro, as well as in Sao Paulo through the Drogaria Iguatemi pharmacy chain. Retail sales are also growing through DS Healthcare’ Brazilian ecommerce site. According to market research firm Euromonitor, the Brazilian beauty industry generated $42 billion in sales in 2012.

“We are experiencing extremely robust sales growth in Brazil while building strong brand recognition and loyalty for our products. While we are successfully achieving market penetration into two of Brazil’s largest cities, we also intend to expand distribution beyond these metropolitan areas into other regions of the country. In addition, we’ve seen our e-commerce platform that services customers in regions where we have yet to be present, do extremely well, further endorsing our belief that Brazil will be one of our key markets worldwide” stated DS Healthcare President and CEO Daniel Khesin. ”

About DS Healthcare Group

DS Healthcare Group Inc. leads in the development of biotechnology for topical therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Healthcare Group’s flagship brand, visit www.dslaboratories.com

WILMINGTON, Mass., Aug. 5, 2014 /PRNewswire/ — Implant Sciences Corporation (IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced its CEO Glenn D. Bolduc has been invited to attend the U.S.-Africa Business Forum on Tuesday, August 5, 2014 in Washington D.C. Mr. Bolduc is one of a select group of U.S. CEOs invited to the event co-hosted by the U.S. Department of Commerce and Bloomberg Philanthropies. Heads of state will engage with business executives from both sides of the Atlantic in conversations about successes and solutions to build greater access for trade and investment in Africa. President Obama will participate in the conversation with CEOs and government leaders from the U.S. and Africa.

The first-ever U.S.-Africa Business Forum will be part of President Obama’s U.S.-Africa Leaders Summit, the first summit of its kind, and the largest event that any U.S. president has ever convened with African heads of state or government.

“I’m honored to be invited to this event on behalf of Implant Sciences. Africa is a key export market for our American-made explosives trace detectors and I look forward to joining the conversation with African executives, heads of state, and President Obama. Through our relationship with the U.S. Department of Commerce, our established sales and distribution network in Africa, and strong record of customer satisfaction, we continue to drive sales in the region. We appreciate the support we’ve received from the U.S. Department of Commerce,” Bolduc stated.

About Implant Sciences

Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company’s team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 50 countries worldwide. Implant Sciences is only the third manufacturer, and the sole American-owned company, to currently have an ETD system named as a Qualified Product by the US Transportation Security Administration. The Company’s ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., STAC in France, the German Ministry of the Interior, and the Ministry of Public Safety in China. It also received a GSN 2013 Homeland Security Award for “Best Explosives Detection Solution”. All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company’s website at www.implantsciences.com.

JERUSALEM, August 7, 2014 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today reports that the last patient has completed treatment in its Phase IIa clinical trial of ORMD-0801, the Company’s proprietary oral insulin capsule, to treat type 1 diabetes, and top-line data is expected to be reported in the fourth quarter of 2014. The trial was conducted in the United States under a Food and Drug Administration Investigational New Drug protocol.

The prospective, randomized, double-blind, placebo controlled study in patients with established type 1 diabetes is evaluating the safety and impact of ORMD-0801 on the exogenous insulin requirements in 24 type 1 diabetics patients.

About Type 1 Diabetes

Type 1 diabetes is an autoimmune disease in which the pancreatic beta cells responsible for insulin secretion are attacked by the immune system. In the absence of self-produced insulin and the concomitant glycemic control, there is a need to supply extraneous insulin in order to regain glycemic control and prevent future disease complications that include heart disease, blood vessels disease, nerve and eye disease, infections, hypoglycemic events and many more ailments. According to the International Diabetes Federation, type 1 diabetes is on the rise at a rate of 3% per year and currently affects approximately 36 million people worldwide – about 10% of the global diabetes population. The disease was formerly known as juvenile diabetes, and currently affects both pediatric and adult populations.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD[TM]) technology is based on over 30 years of research by top research scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801), having completed separate Phase IIa clinical trials, and anticipating the initiation of separate Phase IIb clinical trials, in patients with both type 1 and type 2 diabetes under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral GLP-1 analog capsule (ORMD-0901). For more information, the content of which is not part of this press release, please visit: http://www.oramed.com

PETACH TIKVA, Israel, Aug. 6, 2014 /PRNewswire/ — Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today new data from a retrospective analysis of its autoimmune disease advanced trials that shows high efficacy of its orally bioavailable drug CF101.

The retrospective study, conducted by a third party statistician group, analyzed the correlation between response to CF101 and patients’ body mass index (BMI) in the Phase II/III Psoriasis interim results as well as the recently completed Phase II Rheumatoid Arthritis trial. The data shows a significant increase in the response to CF101 in patients with a BMI of over 25 in both studies. These findings corroborate the efficacy seen with other FDA approved drugs such as Cyclosporine A which was more effective in patients with high BMI. The company believes these findings will enable it to optimize the design of its forthcoming Phase III studies.

“These new findings are further evidence of CF101’s high efficacy, while the drug continues to show excellent safety in patients. We believe the data will be very important to the design of our forthcoming Phase III trials because these findings help us to achieve the maximum potential of the drug in the treatment of inflammatory conditions,” stated Can-Fite CEO Pnina Fishman.

Can-Fite’s Phase II/III Psoriasis trial is ongoing with data expected to be released in the first quarter of 2015. The Psoriasis therapeutic market was worth $3.6 billion in 2010 and is forecast to grow to $6.7 billion by 2018, according to Global Data. The market is dominated by biological drugs that are primarily administered via intravenous injection (IV) and have potential side effects.

The global Rheumatoid Arthritis drug market is expected to generate revenues of $38.5 billion in 2017, according to Visiongain.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA) is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer and inflammatory diseases. The Company’s CF101 is in Phase II/III trials for the treatment of psoriasis and the Company is preparing for a Phase III CF101 trial for rheumatoid arthritis. Can-Fite’s liver cancer drug CF102 is commencing Phase II trials and has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. CF102 has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. These drugs have an excellent safety profile with experience in over 1,200 patients in clinical studies to date. For more information please visit: www.can-fite.com